SA-E

SA-E is a peptide amphiphile (PA) nanostructure platform designed for enhanced drug delivery to tumors. Unlike traditional stable PA structures, SA-E is engineered to be weakly assembled, allowing it to disassemble in the blood and reassemble with endogenous lipoproteins (LPs). This "hitchhiking" mechanism significantly prolongs blood circulation and enables the platform to cross endothelial barriers via transcytosis. SA-E demonstrates high tumor accumulation across a wide range of cancer types, including breast, colon, pancreatic, and brain cancers, through a lipid-raft-mediated cellular uptake mechanism that is independent of LP receptors. The platform can be conjugated with potent cytotoxic agents, such as monomethyl auristatin E (MMAE), to create therapeutic conjugates (e.g., SA-E-MMAE) that show strong antitumor efficacy with reduced systemic side effects in preclinical models.

Other names

peptide amphiphile SA-E